Navigation Links
VirtualScopics Reports 3rd Quarter 2011 Results; YTD Revenues Rise 9%

ROCHESTER, N.Y., Nov. 10, 2011 /PRNewswire/ -- VirtualScopics, Inc. (NASDAQ: VSCP), a leading provider of quantitative imaging for clinical trials, today reported year to date revenues of $10,780,710 for the nine months ended September 30, 2011 compared to $9,883,190 in the comparable period in 2010, a 9% increase. Third quarter 2011 revenues were $3,268,807 compared to revenues of $3,590,591 in the third quarter of 2010, a 9% decrease. Gross profit for the quarter ended September 30, 2011 was $1,496,626 compared to $1,887,281 for the quarter ended September 30, 2010. Operating income for the third quarter of 2011 was $19,559 compared to $400,235 in the third quarter of 2010. Earnings before interest, taxes, depreciation and amortization, and excluding stock compensation expense and gain on derivative financial instrument ("Adjusted EBITDA") for the third quarter of 2011 was $341,669 compared to $758,636 in the comparable period in 2010. Net income for the quarter ended September 30, 2011 was $562,926 compared to $628,699 for the quarter ended September 30, 2010. The cash balance as of September 30, 2011 was $5,172,413 compared to $4,576,060 as of December 31, 2010.

"During the third quarter we were pleased with advancements we made both operationally and within our R&D initiatives," stated Jeff Markin, president and chief executive officer of VirtualScopics. He added, "Our third quarter revenue was negatively impacted by the slower than anticipated ramp-up of several studies initiated earlier in the year, the delay of studies due to start in the third quarter, and the slowdown of a large phase III study that is moving towards registration with the regulatory authorities earlier than anticipated due to strong patient response."  He further stated, "The impact of these events and the overall softness in the economy are unfortunate, but we are optimistic we will see an uptick in the first half of 2012 given our sales pipeline and the progress we are seeing in our relationship with PPD."  He further stated, "Even with the lower revenues we are pleased to show positive Adjusted EBITDA and an increase to our cash balance."

"Our cash position remains strong and further enables us to invest in market opportunities that support our long-term growth initiatives," said Molly Henderson, chief business and financial officer of VirtualScopics. "As such, we continue to invest in research and development, including new market opportunities, in order to stay innovative with our technology while being prudent with our capital on-hand." She added, "Of significant importance, is that we have filed a 510k with the FDA relative to our first personalized medicine application and accordingly, we've been engaged in several rounds of discussions with potential development partners. We believe quantitative imaging can play a critical role within medical practice and therefore are working towards a broader use of our applications outside of the clinical trial market."  She concluded, "In light of the softness in our third quarter revenues, we are adjusting our 2011 revenue guidance to $14 - $14.5 million, and estimate that our Adjusted EBITDA will range between $1.5 -1.7 million for the full year of 2011 which is in line with the guidance of $1.7 million."

Jeff Markin and Molly Henderson will provide a business and third quarter 2011 financial update during the conference call today at 9:00 a.m. ET.  Interested participants should call 877.407.8035 when calling within the United States or +1 201 689 8035 when calling internationally. This call can also be accessed at and will be available for 30 days after the call.

The Company provides Adjusted EBITDA as a supplemental measure to GAAP regarding the Company's operational performance. The Company defines Adjusted EBITDA as earnings less interest, taxes (if any), depreciation and amortization as further adjusted to exclude stock compensation expense, the gain (loss) on derivative instrument (mark to market adjustment for warrants) and interest income and other expenses.  This financial measure excludes the impact of certain items and, therefore, has not been calculated in accordance with GAAP. The Company's method of calculating Adjusted EBITDA, however, may differ from methods used by other companies, and, as a result, Adjusted EBITDA measures disclosed herein may not be comparable to other similarly titled measures used by other companies. The Company continues to provide information in accordance with GAAP. However, with the adoption of ASC 815-40 and the non-cash variable nature of stock compensation expense (ASC 718) and their very substantial impact on the overall reported net income (loss), the Company believes it is also helpful for investors to receive additional information relating more specifically to the Company's operating results. Accordingly, the Company has presented Adjusted EBITDA which excludes the non-cash effects of ASC 815-40 and ASC 718 on its financial results. Management uses Adjusted EBITDA (a) to evaluate the Company's financial performance, (b) to set internal spending budgets, and (c) to measure operational profitability. In addition, investors have requested these non-GAAP financial measures as a means of providing consistent and comparable information with past reports of financial results. Pursuant to the requirements of Regulation G, the Company has provided a reconciliation of Adjusted EBITDA to the most directly comparable GAAP financial measure, net income, below.

About VirtualScopics, Inc.VirtualScopics, Inc. is a leading provider of imaging solutions to accelerate drug and medical device development.  VirtualScopics has developed a robust software platform for analysis and modeling of both structural and functional medical images.  In combination with VirtualScopics' industry-leading experience and expertise in advanced imaging biomarker measurement, this platform provides a uniquely clear window into the biological activity of drugs and devices in clinical trial patients, allowing sponsors to make better decisions faster.  For more information about VirtualScopics, visit

Forward-Looking Statements The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. These forward-looking statements include, but are not limited to, statements regarding the expected benefits of the Company's investment in infrastructure and new customer contract signings and awards and/or statements preceded by, followed by or that include the words "believes," "could," "expects," "anticipates," "estimates," "intends," "plans," "projects," "seeks," or similar expressions. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements.  Many of these risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2010 filed with the Securities and Exchange Commission (the "SEC"), and in any subsequent reports filed with the SEC, all of which are available at the SEC's website at These include without limitation: the risk of cancellation or delay of customer contracts or specifically as it relates to contact awards, the risk that they may not get signed.  Other risks include the company's dependence on its largest customers and risks of contract performance, protection of our intellectual property and the risks of infringement of the intellectual property rights of others. All forward-looking statements speak only as of the date of this press release and the Company undertakes no obligation to update such forward-looking statements.

-Financial tables to follow-CONTACT:Investor Relations:Company Contact:Tim Ryan

Molly HendersonThe Shoreham Group

Chief Business and Financial Officer, Sr. Vice President80 Eighth Ave, Ste 1107

500 Linden OaksNew York, NY 10011

Rochester, New York 14625+1 212 242.7777 Direct

+1 585  VirtualScopics, Inc. and SubsidiaryCondensed Consolidated Statements of Operations (unaudited)For the Three Months Ended September 30,For the Nine Months Ended September 30,2011201020112010Revenues

$ 3,047,704$ 3,347,205$ 9,973,568$ 9,159,000Reimbursement revenues

221,103243,386807,142724,190Total revenues

3,268,8073,590,59110,780,7109,883,190Cost of services

1,551,0781,459,9245,056,1834,034,589Cost of reimbursement revenues

221,103243,386807,142724,190Total cost of services

1,772,1811,703,3105,863,3254,758,779Gross profit

1,496,6261,887,2814,917,3855,124,41146%53%46%52%Operating expensesResearch and development

320,024270,280984,730789,517Sales and marketing

254,696263,198864,409904,522General and administrative

594,683602,1981,882,8651,825,721Stock-based compensation expense

194,050221,958631,984599,083Depreciation and amortization

113,614129,412364,062381,425Total operating expenses

1,477,0671,487,0464,728,0504,500,268Operating income

19,559400,235189,335624,143Other income (expense)Other income

1,6711,05815,9038,417Other expense

(6,724)(9,316)(24,665)(14,602)Gain on derivative financial instrument

548,420236,722509,621359,857Total other income

543,367228,464500,859353,672Net income

562,926628,699690,194977,815Series B preferred stock cash dividend

12,00040,52036,989140,577Net income attributable to common stockholders

837,238Basic and diluted earnings per common share

.03Weighted average number of common shares outstandingBasic 29,329,81626,313,93728,809,38525,975,864Diluted32,524,65831,039,28433,471,11730,794,874*

Cost of services includes non-cash stock-based compensation expense of $14,446 and $7,031 for thethree months ended September 30, 2011 and 2010, respectively, and $38,465 and $22,691 for the six months endedSeptember 30, 2011 and 2010, respectively.VirtualScopics, Inc. and SubsidiaryCondensed Consolidated Balance SheetsSeptember 30,December 31,20112010Assets(unaudited)Current assetsCash

4,576,060Accounts receivable, net

2,718,6752,727,525Prepaid expenses and other current assets

443,758305,079Total current assets

8,334,8467,608,664Patents, net

1,620,5321,711,501Property and equipment, net

566,078404,426Total assets

9,724,591Liabilities and Stockholders' EquityCurrent liabilitiesAccounts payable and accrued expenses

,099,838Accrued payroll

507,390821,107Unearned revenue

642,103214,508   Derivative liability

316,3772,609,708Total current liabilities

2,246,4934,745,161Commitments and Contingencies

--Stockholders' EquityConvertible preferred stock, $0.001 par value; 15,000,000 shares authorized; Series A 8,400 shares authorized; issued and outstanding, 2,190 and 3,188 at September 30, 2011 and December 31, 2010, respectively; liquidation preference $1,000 per share

23Series B 6,000 shares authorized; issued and outstanding, 600 and 800 at September 30, 2011 and December 31, 2010, respectively; liquidation preference $1,000 per share

11Common Stock, $0.001 par value; 85,000,000 shares authorized; issued and outstanding, 29,370,687 and 27,414,620 shares at September 30, 2011 and December 31, 2010, respectively

29,37127,415Additional paid-in capital

17,693,63815,090,254Accumulated deficit

(9,448,049)(10,138,243)Total stockholders' equity

8,274,9634,979,430Total liabilities and stockholders' equity

9,724,591Three Months EndedThree Months EndedSeptember 30, 2011September 30, 2010(unaudited)

(unaudited)Adjusted EBITDA (non-GAAP measurement):Net income


28,699Interest income and other expenses, net


8,258Depreciation and amortization


129,412Stock-based compensation expense


228,989Gain on derivative financial instrument


(236,722)  Adjusted EBITDA


758,636  Basic Adjusted EBITDA per common share, non-GAAP


.03  Diluted Adjusted EBITDA per common share, non-GAAP


.02Nine Months EndedNine Months EndedSeptember 30, 2011September 30, 2010(unaudited)

(unaudited)Adjusted EBITDA (non-GAAP measurement):Net income


977,815Interest income and other expenses, net


6,185Depreciation and amortization


381,425Stock-based compensation expense


621,774Gain on derivative financial instrument


(359,857)  Adjusted EBITDA


,627,342  Basic Adjusted EBITDA per common share, non-GAAP


.06  Diluted Adjusted EBITDA per common share, non-GAAP



SOURCE VirtualScopics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. VirtualScopics Quantitative Imaging Provides Primary Endpoint in Cartilage Repair Pivotal Clinical Trial
2. VirtualScopics Project Balance Exceeds a Record $35 Million
3. VirtualScopics to Present at the 8th Annual Bio Investor Forum
4. VirtualScopics Schedules Third Quarter 2009 Earnings Announcement
5. VirtualScopics to Present at the Upcoming OneMedPlace Investment Conference
6. VirtualScopics Receives Issuance in Japan of Prominent Patent
7. VirtualScopics Added to Russell Microcap Index
8. VirtualScopics Schedules Second Quarter 2010 Earnings Announcement
9. VirtualScopics and ABX-CRO Collaborate to Enhance Global Molecular Imaging Offerings
10. VirtualScopics to Present at the Upcoming Rodman & Renshaw Annual Global Investment Conference
11. VirtualScopics Revenues Hit Another Quarterly Record
Post Your Comments:
(Date:10/4/2017)... , Oct. 4, 2017  South Korean-based healthcare product ... training aide "cprCUBE" on Kickstarter. The device will educate ... cardiac arrests with better efficiency compared to the dated ... real-time feedback on efficacy of the compression for a ... has a goal to raise $5,000. ...
(Date:10/4/2017)... 4, 2017 OBP Medical , ... medical devices, today announced regulatory approval from ... (or Agência Nacional de Vigilância Sanitária (ANVISA)) to ... surgical retractor with integrated LED light source and ... and exposure of a tissue pocket or cavity ...
(Date:10/2/2017)... 2, 2017  Eli Lilly and Company (NYSE: ... the third quarter of 2017 on Tuesday, October 24, ... that day with the investment community and media to ... conference call will begin at 9 a.m. Eastern time. ... live webcast of the conference call through a link ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... ... and Agile Software Development, has been awarded a contract by the Center for ... Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in a ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... are now treating sleep apnea using cutting-edge Oventus O2Vent technology. As ... serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer ...
(Date:10/12/2017)... ... , ... The American College of Medical Informatics (ACMI) will present the 2017 ... Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is ... pioneer in the field of medical informatics, this prestigious award is presented to an ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a ... of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners ... October 11, 2017. , The annual award competition recognizes editorial and design excellence across ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... nation's first interactive health literacy software tool, and the Cancer Patient Education Network ... cancer patient education, today announce a new strategic alliance. , As CPEN’s ...
Breaking Medicine News(10 mins):